News | August 11, 2024
Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
